Russell Investments Group Ltd. lessened its holdings in shares of Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) by 9.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 429,427 shares of the technology company’s stock after selling 45,840 shares during the period. Russell Investments Group Ltd. owned approximately 0.25% of Cogent Biosciences worth $13,750,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also modified their holdings of COGT. Allspring Global Investments Holdings LLC raised its holdings in Cogent Biosciences by 2.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 15,078 shares of the technology company’s stock worth $476,000 after buying an additional 405 shares during the period. J.Safra Asset Management Corp bought a new position in Cogent Biosciences in the second quarter valued at approximately $27,000. Integrated Wealth Concepts LLC acquired a new position in shares of Cogent Biosciences in the second quarter valued at approximately $29,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Cogent Biosciences by 127.5% in the first quarter. EverSource Wealth Advisors LLC now owns 1,611 shares of the technology company’s stock valued at $62,000 after buying an additional 903 shares during the period. Finally, Parallel Advisors LLC bought a new stake in shares of Cogent Biosciences during the first quarter worth $39,000.
Analyst Ratings Changes
COGT has been the topic of several research reports. HC Wainwright boosted their price objective on shares of Cogent Biosciences from $55.00 to $56.00 and gave the company a “buy” rating in a research report on Monday, November 9th. Piper Sandler upped their target price on shares of Cogent Biosciences from $52.00 to $55.00 and gave the stock an “overweight” rating in a research note on Monday, August 17th. Wall Street Zen cut Cogent Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, September 5th. Guggenheim lifted their price target on Cogent Biosciences from $45.00 to $52.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Finally, Wedbush reissued an “outperform” rating and issued a $55.00 price target on shares of Cogent Biosciences in a research note on Wednesday, September 16th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $53.57.
View Our Latest Stock Report on Cogent Biosciences
Cogent Biosciences Trading Down 0.3%
NASDAQ COGT opened at $27.74 on Friday. Cogent Biosciences, Inc. has a 52 week low of $26.36 and a 52 week high of $43.73. The company has a debt-to-equity ratio of 0.50, a quick ratio of 10.99 and a current ratio of 10.99. The stock’s 50 day moving average price is $30.84 and its two-hundred day moving average price is $35.12. The stock has a market capitalization of $4.83 billion, a price-to-earnings ratio of -12.33 and a beta of 0.36.
Cogent Biosciences (NASDAQ:COGT – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The technology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.03). As a group, analysts anticipate that Cogent Biosciences, Inc. will post -2.37 earnings per share for the current fiscal year.
Cogent Biosciences Profile
Cogent Biosciences is a clinical-stage biotechnology company developing precision medicines for diseases driven by specific genetic mutations. Its research focuses on targeted therapies intended to address the underlying causes of these conditions. The company’s lead investigational medicine, bezuclastinib, is a selective inhibitor of the KIT protein. Cogent has studied it in clinical programs for systemic mastocytosis and gastrointestinal stromal tumors (GIST), conditions in which abnormal KIT signaling can play a role.
Featured Articles
- Five stocks we like better than Cogent Biosciences
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding COGT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report).
Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
